Advances in the treatment of leishmaniasis

Current Opinion in Infectious Diseases

Volumn 15, Issue 6, 2002, Pages 593-598

  Sundar, Shyam ^a   Rai, Madhukar ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Amphotericin B; Kala azar; Leishmaniasis; Sodium stiboglucanate

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; FLUCONAZOLE; IMIQUIMOD; IMMUNOMODULATING AGENT; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; PENTOXIFYLLINE; PLACEBO; SITAMAQUINE; STIBOGLUCONATE SODIUM; TRIAZOLE DERIVATIVE;

CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENCAPSULATION; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LEISHMANIA; LEISHMANIASIS; MAJOR CLINICAL STUDY; METHEMOGLOBINEMIA; MOTION SICKNESS; NEPHROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTOZOAL INFECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT;

EID: 0036919858     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200212000-00007     Document Type: Review

References (37)

1. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian Epidemic. Clin Infect Dis 2000; 31:1104-1107.
2. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6:849-854. A review of drug resistance in India, including evidence and reasons. The author has also discussed the therapeutic approach for treatment and prevention.
3. Lira R, Sundar S, Makharia A, et al. Evidence that the high incidence of treatment failures in Indian Kala-Azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999; 180:564-567.
4. Bryceson ADM. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001; 6:928-934. An excellent article with review and discussion regarding drug resistance in leishmaniasis, choice of drugs, and prevention of primary and secondary resistance.
5. Veeken H, Ritmeijer K, Seaman J, Davidson R. A randomized comparison of branded sodium stibogluconate (Pentostam, GlaxoWellcome, London, UK) and generic sodium stibogluconate (Albert David Ltd, Calcutta, India) for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 2000; 5:312-317.
6. Moore E, O'Flaherty D, Heuvelmans H, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull WHO 2001; 79:388-393.
7. Ritmeijer K, Veeken H, Melaku Y, et al. Ethiopian visceral leishmaniasis: Generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95:668-672. The results of this study have worldwide implications for the treatment of leishmaniasis as generic sodium stibogluconate is found to be as good as branded Pentostam at 1/14th of the cost. This should lead to greater use of generic stibogluconate in all forms of leishmaniasis.
8. v treatment is found to be as good as 20 days of treatment, but children respond poorly irrespective of the duration of treatment.
9. Lessa HA, Machado P, Lima F, et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 2001; 65:87-89. Although carried out on a small number of patients, this uncontrolled study demonstrates an absolutely new approach to the problem of drug resistance.
10. Romero GA, Guerra MV, Paes MG, Macedo VO. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: Therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 2001; 65:456-465. Species specific approach to treatment has been advocated in this study in regions with infections due to multiple Leishmania species.
11. Thakur CP, Kumar K. Efficacy of prolonged therapy with stibogluconate in post-kala-azar dermal leishmaniasis. Ind J Med Res 1990; 91:144-148.
12. Zijlstra EE, el-Hassan AM. Leishmaniasis in Sudan: Post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 2001; 95:S1/59-S1/76. Excellent review of post kala-azar dermal leishmaniasis in Sudan.
13. Garg VK, Agrawal S, Rani S, et al. Post-kala-azar dermal leishmaniasis in Nepal. Int J Dermatol 2001; 40:179-184.
14. Das VN, Ranjan A, Sinha AN, et al. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J Assoc Physicians India 2001; 49:609-613. First study from India with low-close pentamidine and allopurinol combination without any serious pentamidine toxicity in the treatment group.
15. Nacher M, Carme B, Sainte-Marie D, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 2001; 95:331-336. This study demonstrates excellent efficacy of short course pentamidine devoid of toxicity in cutaneous leishmaniasis.
16. Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Meal Hyg 1994; 50:107-111.
17. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharma Des 2002; 8:319-342. Excellent review of antileishmanial drugs; their mechanism of action, pharmacokinetics, future targets and their inhibitors are discussed.
18. Minutes of the Expert Group Meeting on Drug Therapy in Leishmaniasis; 29 August 2000. New Delhi: Indian Council of Medical Research; 2000.
19. Sundar S, Jha TK, Thakur CP, et al. Low dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: A multicenter study. Am J Trop Med Hyg 2002; 66:143-146. First multicenter trial of AmBisome, demonstrating its efficacy at the lowest dose ever.
20. Thakur CP. A single high dose treatment of kala-azar with AmBisome (amphotericin B lipid complex): A pilot study. Int J Antimicrob Agents 2001; 17:67-70.
21. Sundar S, Agrawal G, Rai M, et al. Treatment of Indian visceral leishmaniasis with single or daily infusion of low dose liposomal amphotericin B: Randomized trial. BMJ 2001; 323:419-422. Authors have successfully demonstrated safety and efficacy of single low dose AmBisome, a unique approach to the treatment of visceral leishmaniasis.
22. Sundar S, Agrawal NK, Sinha PR, et al. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis: Unresponsive to antimony. Ann Intern Med 1997; 127:133-137.
23. Dietz R, Milan EP, Berman JD, et al. Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion). Clin Infect Dis 1993; 17:981-986.
24. El-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of old world cutaneous leishmaniasis caused by Leishmania major: A double-blind control study. J Am Acad Dermatol 1992; 27:227-231.
25. Krause G, Kroeger A. Topical treatment of American cutaneous leishmaniasis with paromomycin and methylbenzethonium chloride, a clinical study under field conditions in Ecuador. Trans R Soc Trop Med Hyg 1994; 88:92-94.
26. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, doubleblind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001; 65:466-470. One of a few well designed studies on cutaneous leishmaniasis, demonstrating the clear efficacy of paromomycin methylbenzethonium chloride combination over placebo in Guatemala.
27. Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine treatment for visceral leishmaniasis. Lancet 1998; 352:1821-1824.
28. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341:1795-800.
29. Soto J, Toledo J, Gutierrez P, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33:e57-e61. First report of the efficacy of oral miltefosine in cutaneous leishmaniasis, this study opens up new avenues for the treatment of visceral leishmaniasis. Being an oral drug, its combination with other oral or parenteral compounds can easily be tested in various forms of cutaneous leishmaniasis.
30. Sherwood JA, Gachihi GS, Muigai RK, et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994; 19:1034-1039.
31. Dietze R, Carvalho SF, Valli LC, et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001; 65:685-689.
32. Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891-895. This well designed placebo controlled study successfully demonstrated clear efficacy of fluconazole, devoid of any adverse event, and arms clinicians with another oral compound for the treatment of cutaneous leishmaniasis.
33. v.
34. Mesa C, Rodriquez-Cabezas N, Castilla JJ, et al. In vitro and in vivo activities of three acridine thioethers against Leishmania donovani. Pharmacology 2002; 65:74-82.
35. Barrett MP, Gilber IH. Perspectives for new drugs against trypanosomiasis and leishmaniasis. Curr Topics Med Chem 2002; 2:471-482. This nice and well written article discusses various target enzymes of trypanosomatids for development of drugs against these organisms.
36. Sairafianpour M, Christensen J, Staerk D, et al. Leishmanicidal, antiplasmodial, and cytotoxic activity of novel diterpenoid 1,2-quinones from Perovskia abrotanoides: New source of tanshinones. J Nat Prod 2001; 64:1398-1403.
37. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33:1847-1851. Although there was only a small number of patients and no controls were included, a novel approach to overcome drug resistance in cutaneous leishmaniasis has been demonstrated in this study.